RSS Feeds
Risks of Intravenous Immunoglobulin in Sepsis Affect Trial Design
- Sujoy Khan, MBBS; and
- W. A.C. Sewell, MBBS, PhD
- From Path Links Immunology, Scunthorpe DN15 7BH, United Kingdom.
TO THE EDITOR:
The meta-analysis by Turgeon and colleagues (1) on the use of intravenous immunoglobulin (IVIG) in adults with sepsis suggests that larger trials should be performed incorporating modern sepsis management techniques. However, the authors did not discuss the side effects of using IVIG in sepsis.
All immunologists recognize that immunoglobulin replacement therapy must be withheld in patients with infections because severe reactions commonly develop (2). An audit of adverse reactions in antibody-deficient patients showed that an intercurrent …
